L Number	Hits	Search Text	DB	Time stamp
1	231	(544/344).CCLS.	USPAT; US-PGPUB; EPO; JPO	2002/09/04 14:55
2	591	(514/250).CCLS.	USPAT; US-PGPUB; EPO; JPO	2002/09/04 14:55

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Apr 08  "Ask CAS" for self-help around the clock
 NEWS  3  Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS  4  Apr 09  ZDB will be removed from STN
 NEWS  5  Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS  6  Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS  7  Apr 22  BIOSIS Gene Names now available in TOXCENTER
 NEWS  8  Apr 22  Federal Research in Progress (FEDRIP) now available
 NEWS  9  Jun 03  New e-mail delivery for search results now available
 NEWS 10  Jun 10  MEDLINE Reload
 NEWS 11  Jun 10  PCTFULL has been reloaded
 NEWS 12  Jul 02  FOREGE no longer contains STANDARDS file segment
 NEWS 13  Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
 NEWS 14  Jul 29  Enhanced polymer searching in REGISTRY
 NEWS 15  Jul 30  NETFIRST to be removed from STN
 NEWS 16  Aug 08  CANCERLIT reload
 NEWS 17  Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18  Aug 08  NTIS has been reloaded and enhanced
 NEWS 19  Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
 NEWS 20  Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21  Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22  Aug 26  Sequence searching in REGISTRY enhanced
 NEWS 23  Sep 03  JAPIO has been reloaded and enhanced

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

V. Balasubramanian

```
FILE 'HOME' ENTERED AT 14:48:16 ON 04 SEP 2002

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:48:25 ON 04 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:    3 SEP 2002  HIGHEST RN 446233-03-0
DICTIONARY FILE UPDATES:   3 SEP 2002  HIGHEST RN 446233-03-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Calculated physical property data is now available.  See HELP PROPERTIES
for more information.  See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\STNEXP4\QUERIES\09980186.str

L1      STRUCTURE UPLOADED

=> que L1

L2   QUE L1

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 14:48:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2255 TO ITERATE

 44.3% PROCESSED    1000 ITERATIONS                              3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        42253 TO    47947
PROJECTED ANSWERS:               3 TO      291

L3            3 SEA SSS SAM L1

=> d scan

L3   3 ANSWERS   REGISTRY  COPYRIGHT 2002 ACS
IN   Pyrazino[1,2-a]indole, 6,7-difluoro-1,2,3,4,10,10a-hexahydro-4-methyl-,
     monohydrochloride, (4R,10aS)- (9CI)
MF   C12 H14 F2 N2 . Cl H

Absolute stereochemistry.  Rotation (-).
```



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 3 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Pyrazino[1,2-a]indole-6-carbonitrile, 1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI)
MF C13 H15 N3 . Cl H

Absolute stereochemistry.



● HCl

L3 3 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6,7-trimethyl-, (4R,10aR)- (9CI)
MF C14 H20 N2
CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 14:49:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 46036 TO ITERATE

100.0% PROCESSED 46036 ITERATIONS 185 ANSWERS
SEARCH TIME: 00.00.03

L4 185 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.66	140.87

FILE 'CAPLUS' ENTERED AT 14:49:23 ON 04 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Sep 2002 VOL 137 ISS 10
FILE LAST UPDATED: 3 Sep 2002 (20020903/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
=> s l4
L5          19 L4

=> d l5 1-19 bib hitstr
```

L5 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 2002:575046 CAPLUS
DN 137:119688
TI Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
IN Robichaud, Albert; Mitchell, Ian S.
PA Bristol-Myers Squibb Pharma Company, USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059082	A2	20020801	WO 2001-US49373	20011219

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-256821P P 20001220
OS MARPAT 137:119688
IT **43005-54-5D**, derivs.
RL: PAC (Pharmacological activity); BIOL (Biological study)
(aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands)
RN 43005-54-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 2002:107346 CAPLUS
DN 136:167392
TI Preparation of 1,2,3,4,10,10a-hexahydro-1H-pyrazino[1,2-a]indoles and analogs and 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity
IN Bentley, Jonathan Mark; Hebeisen, Paul; Muller, Marc; Richter, Hans; Roever, Stephan; Mattei, Patrizio; Taylor, Sven
PA F. Hoffmann-La Roche A.-G., Switz.; Vernalis Research Limited
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent

V. Balasubramanian

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010169	A1	20020207	WO 2001-EP8520	20010724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002035110	A1	20020321	US 2001-912949	20010725
PRAI	EP 2000-116517	A	20000731		

OS MARPAT 136:167392

IT **396075-16-4P**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(5-HT agonist; prepn. of pyrazinoindoles and analogs as 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity)

RN 396075-16-4 CAPLUS

CN Pyrazino[1,2-a]indole, 7-bromo-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **396075-25-5P**, (4S,10AS)-7-Bromo-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-26-6P**, (4R,10AR)-7-Bromo-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-34-6P**, (4R,10R,10AR)-4,6,10-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-HT agonist; prepn. of pyrazinoindoles and analogs as 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity)

RN 396075-25-5 CAPLUS

CN Pyrazino[1,2-a]indole, 7-bromo-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4S,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 396075-26-6 CAPLUS
CN Pyrazino[1,2-a]indole, 7-bromo-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396075-34-6 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6,10-trimethyl-, (4R,10R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **396074-62-7P**, (4R,10AR)-6-Ethyl-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396639-64-8P**, (4R,10AR)-7-bromo-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(5-HT agonist; prepn. of pyrazinoindoles and analogs as 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity)

RN 396074-62-7 CAPLUS
CN Pyrazino[1,2-a]indole, 6-ethyl-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396639-64-8 CAPLUS
CN Pyrazino[1,2-a]indole, 7-bromo-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **396074-31-0P**, (10AR)-3-[9-Bromo-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-ylmethyl]oxazolidin-2-one **396074-32-1P**, (10AS)-3-[9-Bromo-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-ylmethyl]oxazolidin-2-one **396074-33-2P**, (10AR)-2-[9-Bromo-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl]ethanol **396074-35-4P 396074-36-5P 396074-37-6P**, (4R,10AR)-7-Chloro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396074-38-7P**, (4R,10AS)-7-Chloro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396074-40-1P**, (4S,10AS)-7-Chloro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396074-41-2P**, (4S,10AR)-7-Chloro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396074-49-0P**, (4R,10AR)-4-Methyl-7-trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-55-8P**, (4R,10AS)-4-Methyl-7-trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-56-9P**, (4R,10AS)-6-Ethyl-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396074-66-1P**, (4R,10AR)-8-Bromo-4-methyl-7-trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-67-2P**, (4R,10AR)-4,6,7-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-70-7P**, (4R,10AR)-7-Bromo-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-74-1P**, (4R,10AR)-4,8-Dimethyl-7-trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-76-3P**, (4R,10AR)-9-Chloro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-80-9P**, (4R,10AS)-4,8-Dimethyl-7-trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-88-7P**, (4R,10AR)-7-Chloro-8-fluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-92-3P**, (4R,10AS)-8-Bromo-4-methyl-7-trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396074-95-6P**, (4R,10AR)-4-methyl-1,2,3,4,10,10a-

hexahydropyrazino[1,2-a]indole-7-carbonitrile hydrochloride **396074-98-9P**, (4R,10AR)-9-Chloro-6-fluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-04-0P**, (4R,10AR)-6,7-Difluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-09-5P**, (4R,10AS)-6,7-Difluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-10-8P**, (4R,10AR)-7-Chloro-6-fluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-20-0P**, (4RS,10aSR)-7-Bromo-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-21-1P**, (4RS,10aRS)-6,7,8-Tribromo-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-22-2P**, (4RS,10aRS)-7,8-Dibromo-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-27-7P**, (4RS,10aSR)-4-Ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-28-8P**, (4RS,10aRS)-4-Ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-29-9P**, (4R,10AR)-8-Bromo-6-ethyl-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-30-2P**, (4R,10S,10AR)-4,6,10-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-35-7P**, (4R,10AR)-8-Fluoro-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-36-8P**, (4R,10AS)-8-Fluoro-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-41-5P**, (4R,10AR)-6-Fluoro-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-42-6P**, (4R,10AS)-6-Fluoro-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-46-0P**, (4R,10AR)-8-Fluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-50-6P**, (4R,10AR)-4,6-Dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-51-7P**, (4R,10AS)-4,6-Dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-54-0P**, (4R,10AR)-7-Bromo-9-fluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-59-5P**, (4R,10AR)-6-Fluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-63-1P**, (4R,10AR)-6,9-Difluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-66-4P**, (4R,10AR)-7,9-Dichloro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-67-5P**, (4R,10AS)-7,9-Dichloro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-70-0P**, (4R,10AR)-4,7,9-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-73-3P**, (4R,10AS)-6-Bromo-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-77-7P**, (4R,10AR)-7-Fluoro-4,6-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-83-5P**, (4R,10AS)-7-Chloro-4,8-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-85-7P**, (4R,10AR)-7-Chloro-4,8-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-87-9P**, (4R,10AR)-4-Methyl-6-trifluoromethoxy-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396075-94-8P**, (4R,10AR)-6-Fluoro-4,9-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396075-95-9P**, (4R,10AS)-6-Fluoro-4,9-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396076-00-9P**, (4R,10AR)-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole-6-carbonitrile hydrochloride **396076-02-1P**, (4R,10AR)-6-Chloro-4,8-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396076-03-2P**, (4R,10AS)-6-Chloro-4,8-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396076-06-5P**, (4R,10AR)-4,6,9-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-07-6P**,

(4R,10AS)-4,6,7-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-08-7P**, (4R,10AS)-4,6,9-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-10-1P**, (4R,10AR)-7-Chloro-4,6-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-11-2P**, (4R,10AS)-7-Chloro-4,6-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-13-4P**, (4RS,10aRS)-7-Chloro-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-15-6P**, (4RS,10aSR)-7-chloro-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-16-7P**, (4R,10AR)-7-Chloro-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-18-9P**, (4R,10AS)-7-Chloro-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-19-0P**, (4S,10AS)-7-Chloro-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-21-4P**, (4S,10AR)-7-Chloro-4-ethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-22-5P**, (4R,10AS)-6-Chloro-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-24-7P**, (4R,10AR)-6-Chloro-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-29-2P**, (4R,10AR)-N-[4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indol-7-yl]acetamide hydrochloride **396076-33-8P**, (4R,10AR)-[4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indol-7-yl]methanol hydrochloride **396076-36-1P**, (4R,10AR)-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole-7-carboxylic acid butylamide hydrochloride **396076-39-4P**, (4R,10AR)-4,8-Dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole trifluoroacetate **396076-40-7P**, (4R,10AR)-8-Bromo-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-41-8P**, (4R,10AS)-8-Bromo-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-48-5P**, (4R,10AS)-4,7-Dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-49-6P**, (4R,10AR)-4,7-Dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-52-1P**, (4R,10AR)-4,7,8-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-53-2P**, (4R,10AS)-4,7,8-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-56-5P**, (4R,10AR)-6,7-Dichloro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-59-8P**, (4R,10AS)-8-Fluoro-4,6-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396076-64-5P**, (4R,10AR)-8-Bromo-7-fluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-71-4P**, (4R,10AS)-8-Bromo-7-fluoro-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-72-5P**, (4R,10AR)-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole-7-carboxylic acid diethylamide hydrochloride **396076-74-7P**, (4R,10AR)-8-Fluoro-4,6-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396076-76-9P**, (4R,10AR)-7-Methoxymethyl-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-78-1P**, (4R,10AR)-7-(2-Methoxyethoxymethyl)-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-80-5P**, (4R,10AR)-6-Bromo-4,7-dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole hydrochloride **396076-86-1P**, (4S,10AS)-(7-Trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indol-4-yl)methanol **396076-87-2P**, (4S,10AR)-(7-Trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indol-4-yl)methanol **396076-92-9P**, (4R,10AR)-4,6-Dimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396076-93-0P**, (4R,10AR)-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole-6-carbonitrile **396639-65-9P**, (4R,10AR)-4,6,7-Trimethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396639-66-0P**, (4R,10AR)-4,8-Dimethyl-7-trifluoromethyl-

1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-HT agonist; prepn. of pyrazinoindoles and analogs as 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity)

RN 396074-31-0 CAPLUS
CN 2-Oxazolidinone, 3-[[(10aR)-9-bromo-3,4,10,10a-tetrahydropyrazino[1,2-a]indol-2(1H)-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-32-1 CAPLUS
CN 2-Oxazolidinone, 3-[[(10aS)-9-bromo-3,4,10,10a-tetrahydropyrazino[1,2-a]indol-2(1H)-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-33-2 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-ethanol, 9-bromo-3,4,10,10a-tetrahydro-, (10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-35-4 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-acetic acid, 9-bromo-3,4,10,10a-tetrahydro-, methyl ester, (10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-36-5 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-acetamide, 9-bromo-3,4,10,10a-tetrahydro-, (10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-37-6 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396074-38-7 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-40-1 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-4-methyl-,

(4S,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 396074-41-2 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-4-methyl-, (4S,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-49-0 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4-methyl-7-(trifluoromethyl)-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-55-8 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4-methyl-7-(trifluoromethyl)-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-56-9 CAPLUS
CN Pyrazino[1,2-a]indole, 6-ethyl-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-66-1 CAPLUS
CN Pyrazino[1,2-a]indole, 8-bromo-1,2,3,4,10,10a-hexahydro-4-methyl-7-(trifluoromethyl)-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-67-2 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6,7-trimethyl-, monohydróchloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-70-7 CAPLUS
CN Pyrazino[1,2-a]indole, 7-bromo-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-74-1 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,8-dimethyl-7-(trifluoromethyl)-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-76-3 CAPLUS
CN Pyrazino[1,2-a]indole, 9-chloro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-80-9 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,8-dimethyl-7-(trifluoromethyl)-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-88-7 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-8-fluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



HCl

RN 396074-92-3 CAPLUS
CN Pyrazino[1,2-a]indole, 8-bromo-1,2,3,4,10,10a-hexahydro-4-methyl-7-(trifluoromethyl)-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396074-95-6 CAPLUS
CN Pyrazino[1,2-a]indole-7-carbonitrile, 1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396074-98-9 CAPLUS
CN Pyrazino[1,2-a]indole, 9-chloro-6-fluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396075-04-0 CAPLUS
CN Pyrazino[1,2-a]indole, 6,7-difluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396075-09-5 CAPLUS
CN Pyrazino[1,2-a]indole, 6,7-difluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396075-10-8 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-6-fluoro-1,2,3,4,10,10a-hexahydro-4-methyl-

, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396075-20-0 CAPLUS
CN Pyrazino[1,2-a]indole, 7-bromo-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396075-21-1 CAPLUS
CN Pyrazino[1,2-a]indole, 6,7,8-tribromo-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396075-22-2 CAPLUS
CN Pyrazino[1,2-a]indole, 7,8-dibromo-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396075-27-7 CAPLUS
CN Pyrazino[1,2-a]indole, 4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396075-28-8 CAPLUS
CN Pyrazino[1,2-a]indole, 4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396075-29-9 CAPLUS
CN Pyrazino[1,2-a]indole, 8-bromo-6-ethyl-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396075-30-2 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6,10-trimethyl-, (4R,10S,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396075-35-7 CAPLUS
CN Pyrazino[1,2-a]indole, 8-fluoro-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-36-8 CAPLUS
CN Pyrazino[1,2-a]indole, 8-fluoro-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 396075-41-5 CAPLUS
CN Pyrazino[1,2-a]indole, 6-fluoro-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-42-6 CAPLUS
CN Pyrazino[1,2-a]indole, 6-fluoro-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-46-0 CAPLUS
CN Pyrazino[1,2-a]indole, 8-fluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-50-6 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6-dimethyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-51-7 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6-dimethyl-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-54-0 CAPLUS
CN Pyrazino[1,2-a]indole, 7-bromo-9-fluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-59-5 CAPLUS
CN Pyrazino[1,2-a]indole, 6-fluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396075-63-1 CAPLUS
CN Pyrazino[1,2-a]indole, 6,9-difluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-66-4 CAPLUS
CN Pyrazino[1,2-a]indole, 7,9-dichloro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-67-5 CAPLUS
CN Pyrazino[1,2-a]indole, 7,9-dichloro-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-70-0 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,7,9-trimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396075-73-3 CAPLUS
CN Pyrazino[1,2-a]indole, 6-bromo-1,2,3,4,10,10a-hexahydro-4-methyl-,

monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-77-7 CAPLUS
CN Pyrazino[1,2-a]indole, 7-fluoro-1,2,3,4,10,10a-hexahydro-4,6-dimethyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-83-5 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-4,8-dimethyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396075-85-7 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-4,8-dimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396075-87-9 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4-methyl-6-(trifluoromethoxy)-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396075-94-8 CAPLUS
CN Pyrazino[1,2-a]indole, 6-fluoro-1,2,3,4,10,10a-hexahydro-4,9-dimethyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396075-95-9 CAPLUS
CN Pyrazino[1,2-a]indole, 6-fluoro-1,2,3,4,10,10a-hexahydro-4,9-dimethyl-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-00-9 CAPLUS
CN Pyrazino[1,2-a]indole-6-carbonitrile, 1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-02-1 CAPLUS
CN Pyrazino[1,2-a]indole, 6-chloro-1,2,3,4,10,10a-hexahydro-4,8-dimethyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-03-2 CAPLUS
CN Pyrazino[1,2-a]indole, 6-chloro-1,2,3,4,10,10a-hexahydro-4,8-dimethyl-,

monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-06-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6,9-trimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396076-07-6 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6,7-trimethyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396076-08-7 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6,9-trimethyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 396076-10-1 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-4,6-dimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-11-2 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-4,6-dimethyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 396076-13-4 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396076-15-6 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396076-16-7 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396076-18-9 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396076-19-0 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4S,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 396076-21-4 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-4-ethyl-1,2,3,4,10,10a-hexahydro-, (4S,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 396076-22-5 CAPLUS
CN Pyrazino[1,2-a]indole, 6-chloro-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396076-24-7 CAPLUS
CN Pyrazino[1,2-a]indole, 6-chloro-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396076-29-2 CAPLUS
CN Acetamide, N-[(4R,10aR)-1,2,3,4,10,10a-hexahydro-4-methylpyrazino[1,2-a]indol-7-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-33-8 CAPLUS
CN Pyrazino[1,2-a]indole-7-methanol, 1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-36-1 CAPLUS
CN Pyrazino[1,2-a]indole-7-carboxamide, N-butyl-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396076-39-4 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,8-dimethyl-, (4R,10aR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 396076-38-3
CMF C13 H18 N2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 396076-40-7 CAPLUS
CN Pyrazino[1,2-a]indole, 8-bromo-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-41-8 CAPLUS
CN Pyrazino[1,2-a]indole, 8-bromo-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-48-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-49-6 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-52-1 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,7,8-trimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-53-2 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,7,8-trimethyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-56-5 CAPLUS
CN Pyrazino[1,2-a]indole, 6,7-dichloro-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-59-8 CAPLUS
CN Pyrazino[1,2-a]indole, 8-fluoro-1,2,3,4,10,10a-hexahydro-4,6-dimethyl-, monohydrochloride, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-64-5 CAPLUS
CN Pyrazino[1,2-a]indole, 8-bromo-7-fluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-71-4 CAPLUS
CN Pyrazino[1,2-a]indole, 8-bromo-7-fluoro-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-72-5 CAPLUS
CN Pyrazino[1,2-a]indole-7-carboxamide, N,N-diethyl-1,2,3,4,10,10a-hexahydro-4-methyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 396076-74-7 CAPLUS
CN Pyrazino[1,2-a]indole, 8-fluoro-1,2,3,4,10,10a-hexahydro-4,6-dimethyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-76-9 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-7-(methoxymethyl)-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-78-1 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-7-[(2-methoxyethoxy)methyl]-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-80-5 CAPLUS
CN Pyrazino[1,2-a]indole, 6-bromo-1,2,3,4,10,10a-hexahydro-4,7-dimethyl-, monohydrochloride, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 396076-86-1 CAPLUS
CN Pyrazino[1,2-a]indole-4-methanol, 1,2,3,4,10,10a-hexahydro-7-(trifluoromethyl)-, (4S,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-87-2 CAPLUS
CN Pyrazino[1,2-a]indole-4-methanol, 1,2,3,4,10,10a-hexahydro-7-(trifluoromethyl)-, (4S,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-92-9 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6-dimethyl-, (4R,10aR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-93-0 CAPLUS
CN Pyrazino[1,2-a]indole-6-carbonitrile, 1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396639-65-9 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,6,7-trimethyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396639-66-0 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4,8-dimethyl-7-(trifluoromethyl)-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **396074-45-6P**, 9-Bromo-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(intermediate; prepn. of pyrazinoindoles and analogs as 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity)
RN 396074-45-6 CAPLUS
CN Pyrazino[1,2-a]indole, 9-bromo-1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



IT **396074-28-5P**, (10AR)-9-Bromo-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396074-30-9P**, (10AS)-9-bromo-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of pyrazinoindoles and analogs as 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity)
RN 396074-28-5 CAPLUS
CN Pyrazino[1,2-a]indole, 9-bromo-1,2,3,4,10,10a-hexahydro-, (10aR)- (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry. Rotation (+).



RN 396074-30-9 CAPLUS
CN Pyrazino[1,2-a]indole, 9-bromo-1,2,3,4,10,10a-hexahydro-, (10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **396074-34-3P 396074-64-9P,** (4R,10AR)-4-Methyl-7-trifluoromethyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396074-65-0P,** (4R,10AR)-8-Bromo-4-methyl-7-trifluoromethyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396074-75-2P,** (4R,10AR)-4,8-Dimethyl-7-trifluoromethyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396074-93-4P,** (4R,10AS)-4-Methyl-7-trifluoromethyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396074-94-5P,** (4R,10AS)-8-Bromo-4-methyl-7-trifluoromethyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396074-96-7P,** (4R,10AR)-7-Bromo-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396074-97-8P,** (4R,10AR)-7-Cyano-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396075-23-3P,** (4RS,10aRS)-7-Bromo-4-ethyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396075-24-4P,** (4RS,10aRS)-7,8-Dibromo-4-ethyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396076-30-5P,** (4R,10AR)-7-(Benzhydrylideneamino)-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396076-31-6P,** (4R,10AR)-7-Amino-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396076-32-7P** **396076-34-9P,** (4R,10AR)-4-Methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2,7-dicarboxylic acid 2-tert-butyl ester **396076-35-0P,** (4R,10AR)-7-Hydroxymethyl-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396076-37-2P,** (4R,10AR)-7-Butylcarbamoyl-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester **396076-73-6P,** (4R,10AR)-7-Diethylcarbamoyl-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester

396076-77-0P, (4R,10AR)-7-Methoxymethyl-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester
396076-79-2P, (4R,10AR)-7-(2-Methoxyethoxymethyl)-4-methyl-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indole-2-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of pyrazinoindoles and analogs as 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity)

RN 396074-34-3 CAPLUS
CN Pyrazino[1,2-a]indole, 9-bromo-2-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-1,2,3,4,10,10a-hexahydro-, (10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-64-9 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 3,4,10,10a-tetrahydro-4-methyl-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-65-0 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 8-bromo-3,4,10,10a-tetrahydro-4-methyl-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-75-2 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 3,4,10,10a-tetrahydro-4,8-dimethyl-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-93-4 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 3,4,10,10a-tetrahydro-4-methyl-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-94-5 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 8-bromo-3,4,10,10a-tetrahydro-4-methyl-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396074-96-7 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-bromo-3,4,10,10a-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396074-97-8 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-cyano-3,4,10,10a-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396075-23-3 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-bromo-4-ethyl-3,4,10,10a-tetrahydro-, 1,1-dimethylethyl ester, (4R,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396075-24-4 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7,8-dibromo-4-ethyl-3,4,10,10a-tetrahydro-, 1,1-dimethylethyl ester, (4R,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 396076-30-5 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-[(diphenylmethylene)amino]-3,4,10,10a-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-31-6 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-amino-3,4,10,10a-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-32-7 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-(acetylamino)-3,4,10,10a-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-34-9 CAPLUS
CN Pyrazino[1,2-a]indole-2,7(1H)-dicarboxylic acid, 3,4,10,10a-tetrahydro-4-methyl-, 2-(1,1-dimethylethyl) ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396076-35-0 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 3,4,10,10a-tetrahydro-7-(hydroxymethyl)-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-37-2 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-[(butylamino)carbonyl]-3,4,10,10a-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-73-6 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-[(diethylamino)carbonyl]-3,4,10,10a-tetrahydro-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-77-0 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 3,4,10,10a-tetrahydro-7-(methoxymethyl)-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396076-79-2 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 3,4,10,10a-tetrahydro-7-[(2-methoxyethoxy)methyl]-4-methyl-, 1,1-dimethylethyl ester, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **396076-01-0**, (4R,10AR)-6-bromo-4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396639-61-5**, (4R,10AR)-4-Methyl-7-trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole **396639-63-7**, (4R,10AS)-4-methyl-7-trifluoromethyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of pyrazinoindoles and analogs as 5-HT receptor agonists for treatment of CNS diseases, cardiovascular disorders, gastrointestinal disorders, and obesity)

RN 396076-01-0 CAPLUS
CN Pyrazino[1,2-a]indole, 6-bromo-1,2,3,4,10,10a-hexahydro-4-methyl-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 396639-61-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4-methyl-7-(trifluoromethyl)-, (4R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 396639-63-7 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-4-methyl-7-(trifluoromethyl)-, (4R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 2001:10085 CAPLUS
DN 134:86238
TI Preparation of pyrazole derivatives as antitumor agents
IN Ejima, Akio; Ohsuki, Satoru; Ohki, Hitoshi; Naito, Hiroyuki
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO U.S., 51 pp., Cont.-in-part of Appl. No. PCT/JP98/00300.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6169086	B1	20010102	US 1999-359419	19990723
	WO 9832739	A1	19980730	WO 1998-JP300	19980126

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GM, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRAI	JP 1997-12116	A	19970127
	WO 1998-JP300	A2	19980126
	JP 1998-208807	A	19980724

OS MARPAT 134:86238

V. Balasubramanian

IT **316359-37-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazole derivs. as antitumor agents)
RN 316359-37-2 CAPLUS
CN 2,4-Pyrimidinediamine, N4,N4-dimethyl-6-[5-methyl-4-[(1E)-3-(3,4,10,10a-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)-1-propenyl]-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

IT **43005-54-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrazole derivs. as antitumor agents)
RN 43005-54-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 2000:535145 CAPLUS
DN 133:150579
TI Preparation of hexahydropyrazino[1,2-a]indoles as 5-HT2 receptor ligands
IN Adams, David Reginald; Bentley, Jon Mark; Davidson, James; Duncton, Matthew Alexander James; Porter, Richard Hugh Phillip
PA Vernalis Research Limited, UK
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000044753	A1	20000803	WO 2000-GB244	20000128

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1147110 A1 20011024 EP 2000-901240 20000128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

BR 2000008979 A 20020205 BR 2000-8979 20000128

PRAI GB 1999-2047 A 19990129
WO 2000-GB244 W 20000128

OS MARPAT 133:150579

IT **287384-36-5P 287384-37-6P 287384-38-7P**
287384-39-8P 287384-40-1P 287384-41-2P
287384-42-3P 287384-43-4P 287384-44-5P
287384-47-8P 287384-48-9P 287384-49-0P
287384-50-3P 287384-51-4P 287384-52-5P
287384-53-6P 287384-54-7P 287384-56-9P
287384-57-0P 287384-58-1P 287384-59-2P
287384-64-9P 287385-11-9P 287385-14-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hexahydropyrazino[1,2-a]indoles as 5-HT2 receptor ligands)

RN 287384-36-5 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



RN 287384-37-6 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 287384-38-7 CAPLUS
CN Pyrazino[1,2-a]indole, 8-chloro-1,2,3,4,10,10a-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 287384-39-8 CAPLUS
CN Pyrazino[1,2-a]indole, 8-chloro-1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



RN 287384-40-1 CAPLUS
CN Pyrazino[1,2-a]indole, 9-chloro-1,2,3,4,10,10a-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 287384-41-2 CAPLUS
CN Pyrazino[1,2-a]indole, 9-chloro-1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



RN 287384-42-3 CAPLUS
CN Pyrazino[1,2-a]indole, 7-bromo-1,2,3,4,10,10a-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 287384-43-4 CAPLUS
CN Pyrazino[1,2-a]indole, 7-bromo-1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



RN 287384-44-5 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-8-methyl- (9CI) (CA INDEX NAME)



RN 287384-47-8 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-, monohydrochloride, (10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 287384-48-9 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-, (10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287384-49-0 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-, monohydrochloride, (10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 287384-50-3 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-, (10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287384-51-4 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-3-methyl-, monohydrochloride, (3R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

RN 287384-52-5 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-3-methyl-, (3R,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287384-53-6 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-3-methyl-, monohydrochloride, (3R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 287384-54-7 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-3-methyl-, (3R,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287384-56-9 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-3-methyl-, monohydrochloride, (3S,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 287384-57-0 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-8-fluoro-1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



RN 287384-58-1 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-8-fluoro-1,2,3,4,10,10a-hexahydro-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 287384-57-0
CMF C11 H12 Cl F N2



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 287384-59-2 CAPLUS
CN Pyrazino[1,2-a]indole, 8-chloro-1,2,3,4,10,10a-hexahydro-, (10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287384-64-9 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-8-methyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 287384-44-5
CMF C12 H15 Cl N2



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



RN 287385-11-9 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-3-methyl-, (3S,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287385-14-2 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-7-(methylthio)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 287385-13-1
CMF C12 H16 N2 S



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



IT **287384-89-8P 287384-92-3P**
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of hexahydropyrazino[1,2-a]indoles as 5-HT2 receptor ligands)

RN 287384-89-8 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-2-(trifluoroacetyl)-, (10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287384-92-3 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-2-(trifluoroacetyl)-, (10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

IT **287384-87-6P 287385-07-3P 287385-08-4P**
287385-09-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of hexahydropyrazino[1,2-a]indoles as 5-HT2 receptor ligands)

RN 287384-87-6 CAPLUS
CN Pyrazino[1,2-a]indole, 7-chloro-1,2,3,4,10,10a-hexahydro-2-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 287385-07-3 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-7-iodo- (9CI) (CA INDEX NAME)



RN 287385-08-4 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 3,4,10,10a-tetrahydro-7-iodo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 287385-09-5 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 3,4,10,10a-tetrahydro-7-(methylthio)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 2000:84798 CAPLUS
DN 132:137383
TI Preparation of pyrazole derivatives as antitumor agents
IN Ejima, Akio; Ohsuki, Satoru; Ohki, Hitoshi; Naito, Hiroyuki; Makino, Chie
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005230	A1	20000203	WO 1999-JP3962	19990723
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9948002	A1	20000214	AU 1999-48002	19990723
	EP 1103551	A1	20010530	EP 1999-931515	19990723
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2000169475	A2	20000620	JP 1999-211211	19990726
	NO 2001000405	A	20010322	NO 2001-405	20010123
PRAI	JP 1998-208807	A	19980724		
	JP 1998-274459	A	19980929		
	WO 1999-JP3962	W	19990723		

OS MARPAT 132:137383
IT **256928-95-7P 256928-99-1P 256929-00-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazole derivs. as antitumor agents)
RN 256928-95-7 CAPLUS
CN 4-Pyrimidinamine, 2-[5-methyl-4-[(1E)-3-(3,4,10,10a-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)-1-propenyl]-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 256928-99-1 CAPLUS
CN 4-Pyrimidinamine, 2-[4-[(1E)-3-(7-fluoro-3,4,10,10a-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)-1-propenyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 256929-00-7 CAPLUS
CN 4-Pyrimidinamine, 2-[4-[(1E)-3-(9-fluoro-3,4,10,10a-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)-1-propenyl]-5-methyl-1H-pyrazol-1-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● HCl

IT **43005-54-5**

V. Balasubramanian

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrazole derivs. as antitumor agents)
RN 43005-54-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



IT **256930-19-5P 256930-23-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of pyrazole derivs. as antitumor agents)
RN 256930-19-5 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 7-fluoro-3,4,10,10a-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 256930-23-1 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 9-fluoro-3,4,10,10a-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1999:21683 CAPLUS
DN 130:81526
TI Preparation of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates as fibrinogen receptor antagonists
IN Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C.
PA Merck and Co., Inc., USA
SO U.S., 78 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5854245	A	19981229	US 1997-883108	19970626

V. Balasubramanian

OS MARPAT 130:81526

IT **201808-21-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates as fibrinogen receptor antagonists)

RN 201808-21-1 CAPLUS

CN Acetic acid, [4-[[(1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indol-8-yl)carbonyl]amino]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



IT **201809-43-0P 201809-45-2P 201809-47-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-[(4-piperazinobeznoyl)amino]phenyl(oxy)alkanoates as fibrinogen receptor antagonists)

RN 201809-43-0 CAPLUS

CN Pyrazino[1,2-a]indole-2,8(1H)-dicarboxylic acid, 3,4,10,10a-tetrahydro-, 2-(1,1-dimethylethyl) 8-methyl ester (9CI) (CA INDEX NAME)



RN 201809-45-2 CAPLUS

CN Pyrazino[1,2-a]indole-2,8(1H)-dicarboxylic acid, 3,4,10,10a-tetrahydro-, 2-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 201809-47-4 CAPLUS

CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 8-[[[4-(2-ethoxy-2-oxoethoxy)-2-methylphenyl]amino]carbonyl]-3,4,10,10a-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1998:55617 CAPLUS
DN 128:128034
TI Preparation of heterocyclyl-containing O-substituted alcoholamines as fibrinogen receptor antagonist prodrugs
IN Young, Steven D.; Hartman, George D.; Libby, Laura A.; Egbertson, Melissa S.; Slaughter, Donald E.
PA Hartman, George D., USA; Libby, Laura A.; Egbertson, Melissa S.; Slaughter, Donald E.; Merck + Co., Inc.; Young, Steven D.
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9800401	A1	19980108	WO 1997-US11047	19970625
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2257950	AA	19980108	CA 1997-2257950	19970625
	AU 9735037	A1	19980121	AU 1997-35037	19970625
	AU 719102	B2	20000504		
	EP 912513	A1	19990506	EP 1997-931401	19970625
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000513375	T2	20001010	JP 1998-504266	19970625
	US 5932582	A	19990803	US 1997-883107	19970626
PRAI	US 1996-20877P	P	19960628		
	GB 1996-17899	A	19960828		
	WO 1997-US11047	W	19970625		

OS MARPAT 128:128034
IT **201852-88-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyl-contg. O-substituted alcoholamines as fibrinogen receptor antagonist prodrugs)
RN 201852-88-2 CAPLUS
CN Pyrazino[1,2-a]indole-8-carboxamide, N-[4-(2-aminoethoxy)-2-methylphenyl]-1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



IT **201809-43-0P 201809-45-2P 201853-00-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclyl-contg. O-substituted alcoholamines as fibrinogen receptor antagonist prodrugs)

RN 201809-43-0 CAPLUS
CN Pyrazino[1,2-a]indole-2,8(1H)-dicarboxylic acid, 3,4,10,10a-tetrahydro-, 2-(1,1-dimethylethyl) 8-methyl ester (9CI) (CA INDEX NAME)



RN 201809-45-2 CAPLUS
CN Pyrazino[1,2-a]indole-2,8(1H)-dicarboxylic acid, 3,4,10,10a-tetrahydro-, 2-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 201853-00-1 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 8-[[[4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]-2-methylphenyl]amino]carbonyl]-3,4,10,10a-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1998:55525 CAPLUS

V. Balasubramanian

DN 128:128032
TI Preparation of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists
IN Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C.
PA Merck + Co., Inc., USA; Duggan, Mark E.; Egbertson, Melissa S.; Hartman, George D.; Young, Steven D.; Ihle, Nathan C.
SO PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9800134	A1	19980108	WO 1997-US11133	19970625
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2258093	AA	19980108	CA 1997-2258093	19970625
	AU 9735798	A1	19980121	AU 1997-35798	19970625
	AU 721130	B2	20000622		
	EP 912175	A1	19990506	EP 1997-932307	19970625
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000514061	T2	20001024	JP 1998-504291	19970625
PRAI	US 1996-20975P	P	19960628		
	GB 1997-893	A	19970117		
	WO 1997-US11133	W	19970625		

OS MARPAT 128:128032
IT **201808-21-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists)
RN 201808-21-1 CAPLUS
CN Acetic acid, [4-[[(1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indol-8-yl)carbonyl]amino]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



IT **201809-43-0P 201809-45-2P 201809-47-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclyl-substituted phenoxyalkanoic acids as fibrinogen receptor antagonists)
RN 201809-43-0 CAPLUS
CN Pyrazino[1,2-a]indole-2,8(1H)-dicarboxylic acid, 3,4,10,10a-tetrahydro-,

2-(1,1-dimethylethyl) 8-methyl ester (9CI) (CA INDEX NAME)



RN 201809-45-2 CAPLUS
CN Pyrazino[1,2-a]indole-2,8(1H)-dicarboxylic acid, 3,4,10,10a-tetrahydro-, 2-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 201809-47-4 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboxylic acid, 8-[[[4-(2-ethoxy-2-oxoethoxy)-2-methylphenyl]amino]carbonyl]-3,4,10,10a-tetrahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1996:722512 CAPLUS
DN 126:59972
TI Preparation of 3-piperazinomethylpyrrolo[2,3-b]pyridines as dopamine D4 receptor antagonists
IN Baker, Raymond; Kulagowski, Janusz J.; Curtis, Neil R.; Leeson, Paul D.; Ridgill, Mark P.; Smith, Adrian L.
PA Merck, Sharp & Dohme Ltd., UK
SO U.S., 19 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5576319	A	19961119	US 1994-296574	19940826

OS MARPAT 126:59972
IT **158985-24-1P**

V. Balasubramanian

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-piperazinomethylpyrrolo[2,3-b]pyridines as dopamine D4 receptor antagonists)

RN 158985-24-1 CAPLUS

CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)- (9CI) (CA INDEX NAME)



IT **43005-54-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 3-piperazinomethylpyrrolo[2,3-b]pyridines as dopamine D4 receptor antagonists)

RN 43005-54-5 CAPLUS

CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2002 ACS

AN 1996:457805 CAPLUS

DN 125:114494

TI Preparation of pyrido[3,4-b]indoles and pyrazino[1,2-a]indoles as serotonergic agents

IN Commons, Thomas Joseph; Laclair, Christa Marie; Christman, Susan

PA American Home Products Corporation, USA

SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9612721	A1	19960502	WO 1995-US13124	19951003
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5466688	A	19951114	US 1994-326435	19941020
	AU 9538314	A1	19960515	AU 1995-38314	19951003
PRAI	US 1994-326433		19941020		
	US 1994-326435		19941020		
	WO 1995-US13124		19951003		

V. Balasubramanian

OS MARPAT 125:114494

IT **179111-87-6P 179111-89-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrido[3,4-b]indoles and pyrazino[1,2-a]indoles as serotonergic agents)

RN 179111-87-6 CAPLUS

CN 1H-Azepine, hexahydro-1-[1-oxo-2-phenyl-4-(3,4,10,10a-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179111-89-8 CAPLUS

CN 1H-Azepine, hexahydro-1-[1-oxo-2-phenyl-4-(3,4,10,10a-tetrahydropyrazino[1,2-a]indol-2(1H)-yl)butyl]- (9CI) (CA INDEX NAME)



IT **43005-54-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrido[3,4-b]indoles and pyrazino[1,2-a]indoles as serotonergic agents)

RN 43005-54-5 CAPLUS

CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2002 ACS

AN 1995:801121 CAPLUS

DN 124:8013

TI Structure-activity relationship studies of CNS agents. Part 23. N-(3-phenylpropyl)- and N-[(E)-cinnamyl]-1,2,3,4-tetrahydroisoquinoline mimic 1-phenylpiperazine at 5-HT1A receptors

AU Mokrosz, Jerzy L.; Bojarski, Andrzej J.; Charakchieva-Minol, Sijka; Duszynska, Beata; Mokrosz, Maria J.; Paluchowska, Maria H.

V. Balasubramanian

CS Institute Pharmacology, Polish Academy Sciences, Krakow, 31-343, Pol.
SO Archiv der Pharmazie (Weinheim, Germany) (1995), 328(7-8), 604-8
CODEN: ARPMAS; ISSN: 0365-6233
PB VCH
DT Journal
LA English
OS CASREACT 124:8013
IT **43005-54-5 171415-40-0**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(QSAR of CNS agents N-(3-phenylpropyl)- and N-[(E)-cinnamyl]-1,2,3,4-tetrahydroisoquinoline as 1-phenylpiperazine mimics at 5-HT1A receptors)
RN 43005-54-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



RN 171415-40-0 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-, conjugate monoacid (9CI) (CA INDEX NAME)



● H^+

L5 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1995:609441 CAPLUS
DN 123:74225
TI Structure-activity relationship studies of CNS agents. XVII. Spiro[piperidine-4',1-(1,2,3,4-tetrahydro-.beta.-carboline)] as a probe defining the extended topographic model of 5-HT1A receptors
AU Mokrosz, Maria J.; Duszynska, Beata; Bojarski, Andrzej J.; Mokrosz, Jerzy L.
CS Inst. Pharmacology, Polish Acad. Sci., Krakow, 31-343, Pol.
SO Bioorganic & Medicinal Chemistry (1995), 3(5), 533-8
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier
DT Journal
LA English
IT **43005-54-5**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(structure-activity relationship of spiro[piperidine(hydrocarboline)] analogs as ligands of serotoninergic S1A receptors for defining topog. model)

V. Balasubramanian

RN 43005-54-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1994:700925 CAPLUS
DN 121:300925
TI Pyrrolo-pyridine derivatives
IN Baker, Raymond; Curtis, Neil Roy; Kulagowski, Janusz Jozef; Leeson, Paul David; Ridgill, Mark Peter; Smith, Adrian Leonard
PA Merck Sharp and Dohme Limited, UK
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9420497	A1	19940915	WO 1994-GB337	19940221
	W: BB, BG, BR, BY, CN, CZ, FI, HU, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN				
	RW: BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	BR 9406128	A	19960227	BR 1994-6128	19940221
	HU 71799	A2	19960228	HU 1995-1871	19940221
	CN 1118598	A	19960313	CN 1994-191350	19940221
	CA 2116213	AA	19940902	CA 1994-2116213	19940222
	EP 623618	A2	19941109	EP 1994-200426	19940222
	EP 623618	A3	19970402		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5432177	A	19950711	US 1994-200113	19940222
	AU 9456470	A1	19940908	AU 1994-56470	19940228
	AU 674373	B2	19961219		
	ZA 9401368	A	19941028	ZA 1994-1368	19940228
	JP 06279442	A2	19941004	JP 1994-31241	19940301
	ZA 9405699	A	19950307	ZA 1994-5699	19940801
	US 5622950	A	19970422	US 1995-459993	19950602
	NO 9503406	A	19951031	NO 1995-3406	19950830
	FI 9504088	A	19950831	FI 1995-4088	19950831
	US 5712285	A	19980127	US 1996-626099	19960403
PRAI	GB 1993-4111		19930301		
	GB 1993-16275		19930805		
	WO 1994-GB337		19940221		
	US 1994-200113		19940222		
	US 1995-296574		19950826		

OS MARPAT 121:300925
IT **43005-54-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of (piperazinylmethyl)pyrrolo[2,3-b]pyridines dopaminergic D4 antagonists)
RN 43005-54-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



IT **158985-24-1P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (piperazinylmethyl)pyrrolo[2,3-b]pyridines dopaminergic D4 antagonists)
RN 158985-24-1 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-2-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1994:45188 CAPLUS
DN 120:45188
TI Structure-activity relationship studies of CNS agents on the bioactive conformation of 1-arylpiperazines once more
AU Mokrosz, Jerzy L.; Boksa, Jan; Bojarski, Andrzej J.; Charakchieva-Minol, Sijka
CS Inst. Pharmacol., Pol. Acad. Sci., Krakow, 31-343, Pol.
SO Med. Chem. Res. (1993), 3(4), 240-8
CODEN: MCREEB; ISSN: 1054-2523
DT Journal
LA English
IT **43005-54-5P 152193-86-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and binding to serotoninergic S1A and S2 receptors of, twisted conformation in relation to)
RN 43005-54-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



RN 152193-86-7 CAPLUS
CN Pyrazino[1,2-a]indole, 2-ethyl-1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)

V. Balasubramanian



IT **152193-89-0P 152193-90-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 152193-89-0 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 152193-90-3 CAPLUS
CN Pyrazino[1,2-a]indole, 2-ethyl-1,2,3,4,10,10a-hexahydro-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L5 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1980:104099 CAPLUS
DN 92:104099
TI Effects of pyroxamidine and guanethidine on contractile responses to field stimulation and to noradrenaline in the anococcygeus muscle and vas deferens of the rat
AU Doggrell, Sheila A.
CS Dep. Pharmacol. Clin. Pharmacol., Univ. Auckland, Auckland, N. Z.
SO J. Pharm. Pharmacol. (1979), 31(11), 767-72
CODEN: JPPMAB; ISSN: 0022-3573
DT Journal
LA English
IT **43005-53-4**
RL: BIOL (Biological study)
(noradrenaline stimulation of muscle contraction response to, mechanism of)

V. Balasubramanian

RN 43005-53-4 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboximidamide, 3,4,10,10a-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1976:542981 CAPLUS
DN 85:142981
TI Indoline derivatives
IN Jonas, Rochus
PA Merck Patent G.m.b.H., Ger.
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2504531	A1	19760805	DE 1975-2504531	19750204
	CA 1088536	A1	19801028	CA 1976-244550	19760129
	BE 838143	A2	19760730	BE 1976-7000771	19760130
	DK 7600425	A	19760805	DK 1976-425	19760202
	DK 137571	C	19780911		
	SE 7601073	A	19760805	SE 1976-1073	19760202
	SE 412385	C	19800619		
	FR 2354098	B1	19790518	FR 1976-2757	19760202
	FR 2354098	A1	19780106		
	ES 444867	A1	19770516	ES 1976-444867	19760203
	GB 1485105	A	19770908	GB 1976-4218	19760203
	AT 7600744	A	19790615	AT 1976-744	19760203
	AT 354431	B	19790110		
	NL 7601125	A	19760806	NL 1976-1125	19760204
	JP 51101974	A2	19760908	JP 1976-11808	19760204
PRAI	DE 1975-2504531		19750204		

IT **60555-50-2P 60555-51-3P 60555-52-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 60555-50-2 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 60555-51-3 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-2-(phenylmethyl)-, hydrobromide (9CI) (CA INDEX NAME)



● x HBr

RN 60555-52-4 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-8-methoxy-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1974:27298 CAPLUS
DN 80:27298
TI Pyrazino[1,2-a]indoles
PA Merck Patent G.m.b.H.
SO Fr. Demande, 13 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2163554	A1	19730727	FR 1972-44312	19721213
	FR 2163554	B1	19751017		
	DE 2162422	A	19730620	DE 1971-2162422	19711216
PRAI	DE 1971-2162422		19711216		

IT **43005-53-4P 50871-53-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 43005-53-4 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboximidamide, 3,4,10,10a-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 50871-53-9 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboximidamide, 3,4,10,10a-tetrahydro-8-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **43005-55-6 50871-52-8**
RL: RCT (Reactant)
(reaction of, with cyanamide)
RN 43005-55-6 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 50871-52-8 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-8-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2002 ACS
AN 1973:466402 CAPLUS
DN 79:66402
TI Antihypertensive 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indole-2-carboxamidine
IN Jonas, Rochus; Unger, Richard; Schorscher, Ernst; Schliep, Hans J.
PA Merck Patent G.m.b.H.
SO Ger. Offen., 11 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2162422	A	19730620	DE 1971-2162422	19711216
	DE 2250493	A1	19740418	DE 1972-2250493	19721014
	NL 7215584	A	19730619	NL 1972-15584	19721117
	ZA 7208200	A	19730725	ZA 1972-8200	19721120
	GB 1356898	A	19740619	GB 1972-54056	19721122
	JP 48067299	A2	19730913	JP 1972-121707	19721206
	JP 54017760	B4	19790702		
	CH 582703	A	19761215	CH 1972-17838	19721207
	SE 398122	B	19771205	SE 1972-16184	19721212
	FR 2163554	A1	19730727	FR 1972-44312	19721213
	FR 2163554	B1	19751017		
	BR 7208783	A0	19730920	BR 1972-8783	19721213
	HU 164944	P	19740528	HU 1972-ME1574	19721213
	CS 161971	P	19750610	CS 1972-8562	19721213
	CA 998049	A1	19761005	CA 1972-158723	19721213
	BE 792724	A1	19730614	BE 1972-125299	19721214
	US 3853878	A	19741210	US 1972-314934	19721214
	AT 322557	B	19750526	AT 1972-10656	19721214
	PL 79187	P	19750630	PL 1972-159522	19721214
	DD 102384	C	19731212	DD 1972-167580	19721215
	ES 409637	A1	19760301	ES 1972-409637	19721215
	RO 62850	P	19771115	RO 1972-73176	19721216
	JP 54084598	A2	19790705	JP 1978-129421	19781020
PRAI	DE 1971-2162422		19711216		
	DE 1972-2250493		19721014		

IT **43005-52-3P 43005-53-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 43005-52-3 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboximidamide, 3,4,10,10a-tetrahydro- (9CI) (CA INDEX NAME)



RN 43005-53-4 CAPLUS
CN Pyrazino[1,2-a]indole-2(1H)-carboximidamide, 3,4,10,10a-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **43005-55-6**
RL: RCT (Reactant)
(reaction of, with cyanamide)
RN 43005-55-6 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **43005-54-5**
RL: RCT (Reactant)
(reaction of, with methylisothiourea)
RN 43005-54-5 CAPLUS
CN Pyrazino[1,2-a]indole, 1,2,3,4,10,10a-hexahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2002 ACS

C:\STNEXP4\QUERIES\09890186.str





chain nodes :
15 16 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13
chain bonds :
10-16 11-15 12-18 13-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-13 10-11 11-12 12-13
exact/norm bonds :
6-9 8-9 8-10 9-13 10-11 10-16 11-12 11-15 12-13 12-18 13-19
exact bonds :
5-7 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 15:CLASS 16:CLASS 18:CLASS 19:CLASS